Trial Profile
A Healthy Volunteer Repeat Dose Study to Evaluate; the Safety, Tolerability, Pharmacokinetics, Effects on the Pharmacokinetics of Midazolam and the Neurokinin 1 Receptor Occupancy of GSK1144814.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Elinzanetant (Primary) ; Midazolam
- Indications Anxiety disorders; Depressive disorders; Schizophrenia; Sleep disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 29 Sep 2010 New trial record